作者
Peter Borchmann,Justin Ferdinandus,Gundolf Schneider,Alden A. Moccia,Richard Greil,Mark P. Hertzberg,Hans-Theodor Eich,Hans-Theodor Eich,Hans-Theodor Eich,Judith Dierlamm,Hans-Theodor Eich,Urban Novak,Julia Meißner,Christian Meyer Zum Büschenfelde,Hans-Theodor Eich,Hans-Theodor Eich,Alexander Fosså,Hans-Theodor Eich,Bernd Hertenstein,Sonja Martin,Christian Meyer Zum Büschenfelde,Sebastian Scholl,Hans-Theodor Eich,Christian Meyer Zum Büschenfelde,Vladan Vučinić,Christian Meyer Zum Büschenfelde,Hans-Theodor Eich,Hans-Theodor Eich,Christian Meyer Zum Büschenfelde,Christian Meyer Zum Büschenfelde,Christian Meyer Zum Büschenfelde,Maike de Wit,Christian Meyer Zum Büschenfelde,Hans-Theodor Eich,Daniël Molin,Hans-Theodor Eich,Christian Meyer Zum Büschenfelde,Bastian von Tresckow,Hans-Theodor Eich,Christian Meyer Zum Büschenfelde,Hans-Theodor Eich,Andreas Rosenwald,Hans-Theodor Eich,Hans-Theodor Eich,Christian Baues,Athanasios Zomas,Hans-Theodor Eich,Markus Dietlein,Carsten Kobe,Hans-Theodor Eich
摘要
Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two cycles.